Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Merus N.V. CS (MRUS)

Merus N.V. CS (MRUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Merus N.V. CS UPPSALALAAN 17 UTRECHT P7 3584 NLD

www.merus.nl P: 31-85-016-2500

Description:

Merus B.V. is a clinical-stage immuno-oncology company developing bispecific antibody therapeutics, referred to as Biclonics. The company's bispecific antibody candidate, MCLA-128, is being evaluated in a Phase 1/2 clinical trial as a potential treatment for HER2-expressing solid tumors; MCLA-117, is being developed as a potential treatment for acute myeloid leukemia and MCLA-158, which is designed to bind to cancer stem cells and is being developed as a potential treatment for colorectal cancer and other solid tumors. Merus B.V. is headquartered in Utrecht, the Netherlands.

Key Statistics

Overview:

Market Capitalization, $K 2,838,151
Enterprise Value, $K 2,633,901
Shares Outstanding, K 58,688
Annual Sales, $ 43,950 K
Annual Net Income, $ -154,940 K
Last Quarter Sales, $ 8,940 K
Last Quarter Net Income, $ -60,150 K
EBIT, $ -156,550 K
EBITDA, $ -154,010 K
60-Month Beta 1.10
% of Insider Shareholders 4.57%
% of Institutional Shareholders 96.14%
Float, K 56,006
% Float 95.43%
Short Volume Ratio 0.23

Growth:

1-Year Return 155.47%
3-Year Return 138.11%
5-Year Return 235.37%
5-Year Revenue Growth 18.34%
5-Year Earnings Growth -63.04%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -1.09 on 02/28/24
Latest Earnings Date 05/02/24
Earnings Per Share ttm -3.04
EPS Growth vs. Prev Qtr -153.49%
EPS Growth vs. Prev Year 39.78%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

MRUS Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -50.61%
Return-on-Assets % -37.56%
Profit Margin % -352.54%
Debt/Equity 0.00
Price/Sales 63.43
Price/Cash Flow N/A
Price/Book 7.70
Book Value/Share 6.17
Interest Coverage -1.54
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar